Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer

Feb. 27, 2023
The IDH1 R132H and ATRX antibodies are the latest additions to Roche’s neuropathology portfolio, which contains 29 biomarkers.

Roche announced the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer.

The IDH1 assay can also detect the IDH1 R132H mutation in acute myeloid leukemia (AML).

Roche’s IDH1 and ATRX assays are optimized and fully automated on the BenchMark series of instruments. The two tests are now available in the U.S. They will likely be available in other non-CE markets later this year and in countries that accept the CE mark in 2024.

Roche release